The NTAGI has decided against any further changes in the dosing gap at the moment. Experts are of the view that the first dose generates adequate antibodies to protect from severe infection, whereas the second dose is primarily a booster shot that enhances the levels of protection.
Posted from: this blog via Microsoft Power Automate.
